Unknown

Dataset Information

0

Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia.


ABSTRACT: Glycogen storage disease type Ia (GSD Ia) is caused by autosomal mutations in glucose-6-phosphatase ? catalytic subunit (G6PC) and can present with severe hypoglycemia, lactic acidosis and hypertriglyceridemia. In both children and adults with GSD Ia, there is over-accumulation of hepatic glycogen and triglycerides that can lead to steatohepatitis and a risk for hepatocellular adenoma or carcinoma. Here, we examined the effects of the commonly used peroxisomal proliferated activated receptor ? agonist, fenofibrate, on liver and kidney autophagy and lipid metabolism in 5-day-old G6pc -/- mice serving as a model of neonatal GSD Ia. Five-day administration of fenofibrate decreased the elevated hepatic and renal triglyceride and hepatic glycogen levels found in control G6pc -/- mice. Fenofibrate also induced autophagy and promoted ?-oxidation of fatty acids and stimulated gene expression of acyl-CoA dehydrogenases in the liver. These findings show that fenofibrate can rapidly decrease hepatic glycogen and triglyceride levels and renal triglyceride levels in neonatal G6pc -/- mice. Moreover, since fenofibrate is an FDA-approved drug that has an excellent safety profile, our findings suggest that fenofibrate could be a potential pharmacological therapy for GSD Ia in neonatal and pediatric patients as well as for adults. These findings may also apply to non-alcoholic fatty liver disease, which shares similar pathological and metabolic changes with GSD Ia.

SUBMITTER: Yavarow ZA 

PROVIDER: S-EPMC7003036 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia.

Yavarow Zollie A ZA   Kang Hye-Ri HR   Waskowicz Lauren R LR   Bay Boon-Huat BH   Young Sarah P SP   Yen Paul M PM   Koeberl Dwight D DD  

Human molecular genetics 20200101 2


Glycogen storage disease type Ia (GSD Ia) is caused by autosomal mutations in glucose-6-phosphatase α catalytic subunit (G6PC) and can present with severe hypoglycemia, lactic acidosis and hypertriglyceridemia. In both children and adults with GSD Ia, there is over-accumulation of hepatic glycogen and triglycerides that can lead to steatohepatitis and a risk for hepatocellular adenoma or carcinoma. Here, we examined the effects of the commonly used peroxisomal proliferated activated receptor α a  ...[more]

Similar Datasets

| S-EPMC6298237 | biostudies-literature
| S-EPMC6707038 | biostudies-literature
| S-EPMC5357851 | biostudies-literature
| S-EPMC5469511 | biostudies-literature
| S-EPMC7104680 | biostudies-literature
| S-EPMC10308164 | biostudies-literature
| S-EPMC5905716 | biostudies-literature
| S-EPMC2889730 | biostudies-literature
2014-06-13 | E-GEOD-45319 | biostudies-arrayexpress
| S-EPMC6483852 | biostudies-literature